Laura Obici

List of Publications by Year
in descending order

182	14,117	18482 62	21540 114
papers	citations	h-index	g-index

192	192	192	8537
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis. Journal of Neurology, 2022, 269, 1905-1912.	3.6	13
2	AA amyloidosis without systemic inflammation: when clinical evidence validates predictions of experimental medicine. Kidney International, 2022, 101, 219-221.	5.2	0
3	AA amyloidosis in inflammatory active malignant paraganglioma. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 137-138.	3.0	3
4	The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort. Seminars in Arthritis and Rheumatism, 2022, 52, 151957.	3.4	7
5	Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms. Frontiers in Molecular Biosciences, 2022, 9, 830006.	3.5	11
6	Realâ€life experience with inotersen in hereditary transthyretin amyloidosis with lateâ€onset phenotype: Data from an earlyâ€access program in Italy. European Journal of Neurology, 2022, 29, 2148-2155.	3.3	13
7	Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 143-155.	3.0	55
8	Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers. Journal of Neurology, 2021, 268, 189-198.	3.6	38
9	INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 783-791.e4.	3.8	16
10	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurology, The, 2021, 20, 49-59.	10.2	93
11	Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability to mediate cholesterol efflux. Journal of Lipid Research, 2021, 62, 100004.	4.2	7
12	Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Neurology and Therapy, 2021, 10, 375-389.	3.2	34
13	Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy. Orphanet Journal of Rare Diseases, 2021, 16, 163.	2.7	8
14	Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. European Journal of Clinical Investigation, 2021, 51, e13598.	3.4	16
15	Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 2021, 23, 895-905.	7.1	57
16	Ocular Involvement in Hereditary Amyloidosis. Genes, 2021, 12, 955.	2.4	33
17	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndromeâ€"Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. Frontiers in Medicine, 2021, 8, 668173.	2.6	6
18	Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3218-3220.e1.	3.8	4

#	Article	IF	Citations
19	Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR. Neurology and Therapy, 2021, 10, 865-886.	3.2	9
20	Age-related amyloidosis outside the brain: A state-of-the-art review. Ageing Research Reviews, 2021, 70, 101388.	10.9	14
21	HELIOS-A: 9-month results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Journal of the Neurological Sciences, 2021, 429, 117767.	0.6	4
22	Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future. Neurotherapeutics, 2021, 18, 2286-2302.	4.4	8
23	Next generation sequencing panel in undifferentiated autoinflammatory diseases identifies patients with colchicine-responder recurrent fevers. Rheumatology, 2020, 59, 344-360.	1.9	36
24	A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors. Journal of Allergy and Clinical Immunology, 2020, 145, 368-378.e13.	2.9	14
25	Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 97-102.	3.0	31
26	Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. Journal of Neurology, 2020, 267, 1070-1079.	3.6	20
27	ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 259-265.	3.0	51
28	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-Î± Receptorâ€"Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. Mediators of Inflammation, 2020, 2020, 1-12.	3.0	24
29	Understanding the Pathophysiology of Cerebral Amyloid Angiopathy. International Journal of Molecular Sciences, 2020, 21, 3435.	4.1	39
30	Acquired and inherited amyloidosis: Knowledge driving patients' care. Journal of the Peripheral Nervous System, 2020, 25, 85-101.	3.1	12
31	Description of a large cohort of Caucasian patients with <scp>V122I ATTRv</scp> amyloidosis: Neurological and cardiological features. Journal of the Peripheral Nervous System, 2020, 25, 273-278.	3.1	18
32	Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. Mediators of Inflammation, 2020, 2020, 1-6.	3.0	7
33	Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 153-162.	3.0	47
34	Discovering the Italian phenotype of cerebral amyloid angiopathy (CAA): the SENECA project. Neurological Sciences, 2020, 41, 2193-2200.	1.9	3
35	Early data on longâ€term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2â€year update from the openâ€label extension of the NEUROâ€TTR trial. European Journal of Neurology, 2020, 27, 1374-1381.	3.3	49
36	A Narrative Review of the Role of Transthyretin in Health and Disease. Neurology and Therapy, 2020, 9, 395-402.	3.2	47

#	Article	IF	Citations
37	Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients. Blood, 2019, 134, 320-323.	1.4	5
38	Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC: Heart Failure, 2019, 7, 709-716.	4.1	188
39	Assessment of patients with hereditary transthyretin amyloidosis â€“ understanding the impact of management and disease progression. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 103-111.	3.0	40
40	Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. Expert Review of Clinical Pharmacology, 2019, 12, 701-711.	3.1	25
41	Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis. Clinical Autonomic Research, 2019, 29, 55-63.	2.5	21
42	An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis. Expert Opinion on Pharmacotherapy, 2019, 20, 2223-2228.	1.8	9
43	Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 10-14.	3.0	26
44	Burden of hereditary transthyretin amyloidosis on quality of life. Muscle and Nerve, 2019, 60, 169-175.	2.2	39
45	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.9	300
46	AB1305â€…EVALUATION OF SERUM LEVELS OF ASC FOR THE DIAGNOSIS AND MONITORING OF CRYOPYRIN ASSOCIATED PERIODIC SYNDROMES (CAPS). , 2019, , .		0
47	OP0106â€…A NOVEL KNOCK-IN MOUSE MODEL OF CAPS THAT DEVELOPS AMYLOIDOSIS: THERAPEUTIC EFFICACY OF PROTON PUMP INHIBITORS. , 2019, , .		0
48	FRI0568â€…THE USE OF NEXT GENERATION SEQUENCING PANEL IN UNDIFFERENTIATED AUTOINFLAMMATORY DISEASES IDENTIFY A SEPARATE SUBSET OF COLCHICINE-RESPONDER RECURRENT FEVERS DISTINCT FROM PFAPA SYNDROME. , 2019, , .		3
49	Amyloidosis in Heart Failure. Current Heart Failure Reports, 2019, 16, 285-303.	3.3	26
50	Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegenerative Disease Management, 2019, 9, 5-23.	2.2	168
51	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptorâ€“associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436.	2.0	16
52	Seek and You Shall Find: Is Subclinical Amyloid More Common Than Expected?. Mayo Clinic Proceedings, 2018, 93, 1546-1548.	3.0	2
53	Progressive axonal polyneuropathy in a mitochondrial disorder: an uncommon association with familial amyloid neuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 261-262.	3.0	1
54	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. New England Journal of Medicine, 2018, 378, 1908-1919.	27.0	327

#	Article	IF	Citations
55	Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 2018, 379, 22-31.	27.0	1,000
56	Plasminogen activation triggers transthyretin amyloidogenesis in vitro. Journal of Biological Chemistry, 2018, 293, 14192-14199.	3.4	68
57	Becoming familiar with hereditary transthyretin amyloidosis, a treatable neuropathy. Arquivos De Neuro-Psiquiatria, 2018, 76, 573-574.	0.8	1
58	Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Annals of the Rheumatic Diseases, 2017, 76, 173-178.	0.9	96
59	Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 457-458.	1.9	83
60	Prognostication of survival and progression to dialysis in AA amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 136-137.	3.0	9
61	Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome. Annals of the Rheumatic Diseases, 2017, 76, 303-309.	0.9	30
62	Cryopyrin-associated Periodic Syndromes in Italian Patients: Evaluation of the Rate of Somatic NLRP3 Mosaicism and Phenotypic Characterization. Journal of Rheumatology, 2017, 44, 1667-1673.	2.0	28
63	Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system. Journal of Neuroinflammation, 2017, 14, 115.	7.2	16
64	Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Current Opinion in Neurology, 2016, 29, S27-S35.	3.6	86
65	First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Current Opinion in Neurology, 2016, 29, S14-S26.	3.6	179
66	Clinical Characteristics of Patients Carrying the Q703K Variant of the NLRP3 Gene: A 10-year Multicentric National Study. Journal of Rheumatology, 2016, 43, 1093-1100.	2.0	31
67	Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. Journal of Neurology, 2016, 263, 916-924.	3.6	76
68	Expanding the spectrum of systemic amyloid diseases: aÂnew hint from the kidney. Kidney International, 2016, 90, 479-481.	5.2	10
69	Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy. Muscle and Nerve, 2016, 54, 353-360.	2.2	21
70	Clinical Pregenetic Screening for Stroke Monogenic Diseases. Stroke, 2016, 47, 1702-1709.	2.0	34
71	Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome. Journal of Leukocyte Biology, 2016, 99, 761-769.	3.3	15
72	â€œRedâ€flagâ€•symptom clusters in transthyretin familial amyloid polyneuropathy. Journal of the Peripheral Nervous System, 2016, 21, 5-9.	3.1	201

#	Article	IF	Citations
73	Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe. Current Opinion in Neurology, 2016, 29, S3-S13.	3.6	173
74	Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases. Annals of the Rheumatic Diseases, 2016, 75, 1550-1557.	0.9	57
75	Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A caseâ€“control study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 187-193.	3.0	4
76	A practical approach to the diagnosis of systemic amyloidoses. Blood, 2015, 125, 2239-2244.	1.4	156
77	Preliminary assessment of neuropathy progression in patients with hereditary ATTR amyloidosis after orthotopic liver transplantation (OLT). Orphanet Journal of Rare Diseases, 2015, 10, P19.	2.7	8
78	THU0539â€...Clinical Presentation of Cryopyrin-Associated Periodic Syndrome (CAPS) in Carriers of the Q703K Mutation in the CIAS1/NLRP3 Gene: Genotype-Phenotype Characterization of a Family. Annals of the Rheumatic Diseases, 2015, 74, 395.2-395.	0.9	0
79	The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-Î²B pathway. Arthritis Research and Therapy, 2015, 17, 93.	3.5	43
80	Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosis. Kidney International, 2015, 87, 1223-1229.	5.2	28
81	Etiology of Amyloidosis Determines Myocardial 99mTc-DPD Uptake in Amyloidotic Cardiomyopathy. Clinical Nuclear Medicine, 2015, 40, 446-447.	1.3	6
82	Rapid progression of familial amyloidotic polyneuropathy. Neurology, 2015, 85, 675-682.	1.1	109
83	SAT0532â€...Efficacy and Safety of Canakinumab in Patients with Active Recurrent or Chronic TNF-Receptor Associated Periodic Syndrome (TRAPS). Annals of the Rheumatic Diseases, 2015, 74, 852.3-853.	0.9	0
84	Follow-up and management of asymptomatic carriers of amyloidogenic Transthyretin (TTR) gene mutations. Journal of the Neurological Sciences, 2015, 357, e328-e329.	0.6	0
85	An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert Opinion on Investigational Drugs, 2014, 23, 1239-1251.	4.1	47
86	The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Annals of the Rheumatic Diseases, 2014, 73, 2160-2167.	0.9	256
87	Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations. Human Mutation, 2014, 35, E2403-E2412.	2.5	220
88	The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: Clinical manifestations and long-term follow-up. Seminars in Arthritis and Rheumatism, 2014, 43, 818-823.	3.4	71
89	Identification of a new exon 2-skipped TNFR1 transcript: regulation by three functional polymorphisms of the TNFR-associated periodic syndrome (TRAPS) gene. Annals of the Rheumatic Diseases, 2014, 73, 290-297.	0.9	10
90	Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched caseâ€“control study on 174 patients. Leukemia, 2014, 28, 2311-2316.	7.2	113

#	Article	IF	Citations
91	Hereditary apolipoprotein A1 amyloidosis with cutaneous and cardiac involvement: a long familial history. European Journal of Dermatology, 2014, 24, 261-263.	0.6	2
92	Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica, 2014, 99, 743-750.	3.5	138
93	THU0482â€...Gene Expression Profiling of Whole Blood Samples of TRAPS Patients Shows Insight into the Molecular Pathogenesis of TRAPS and Response to Canakinumab Treatment. Annals of the Rheumatic Diseases, 2014, 73, 349.4-350.	0.9	0
94	Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet Journal of Rare Diseases, 2013, 8, 31.	2.7	525
95	Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 142-150.	3.0	106
96	TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients. Neurological Sciences, 2013, 34, 1057-1063.	1.9	43
97	Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis. Journal of Cardiovascular Translational Research, 2013, 6, 1011-1020.	2.4	122
98	Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Annals of the Rheumatic Diseases, 2013, 72, 678-685.	0.9	350
99	Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 173-178.	3.0	24
100	High^{99m}Tc-DPD myocardial uptake in a patient with apolipoprotein AI-related amyloidotic cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 48-51.	3.0	16
101	Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. European Heart Journal, 2013, 34, 520-528.	2.2	252
102	Repurposing Diflunisal for Familial Amyloid Polyneuropathy. JAMA - Journal of the American Medical Association, 2013, 310, 2658.	7.4	551
103	OP0107â€...Clinical features at presentation in a series of 86 patients with genetically confirmed traps and 33 patients with inflammatory symptoms and the r92q variant from the eurofevers/eurotraps registry:. Annals of the Rheumatic Diseases, 2013, 71, 89.2-89.	0.9	0
104	THU0376â€...Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Annals of the Rheumatic Diseases, 2013, 71, 282.3-283.	0.9	1
105	THU0396â€...Efficacy and safety of canakinumab in patients with TNF receptor associated periodic syndrome (TRAPS). Annals of the Rheumatic Diseases, 2013, 71, 289.2-289.	0.9	4
106	First Report of Circulating MicroRNAs in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS). PLoS ONE, 2013, 8, e73443.	2.5	44
107	Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 11-13.	3.0	8
108	Guidelines for the genetic diagnosis of hereditary recurrent fevers. Annals of the Rheumatic Diseases, 2012, 71, 1599-1605.	0.9	160

#	Article	IF	Citations
109	The repertoire of Î» light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood, 2012, 119, 144-150.	1.4	98
110	Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood, 2012, 119, 1844-1847.	1.4	155
111	Amyloidosis in autoinflammatory syndromes. Autoimmunity Reviews, 2012, 12, 14-17.	5.8	96
112	The Diflunisal Trial: Study accrual and drug tolerance. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 37-38.	3.0	39
113	Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 34-36.	3.0	184
114	Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. American Journal of Hematology, 2012, 87, 465-471.	4.1	95
115	Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Annals of Hematology, 2012, 91, 89-92.	1.8	78
116	Amyloid Typing: Immunoelectron Microscopy. , 2012, , 249-260.		2
117	AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Medical Weekly, 2012, 142, w13580.	1.6	87
118	Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 96-97.	3.0	4
119	Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 64-66.	3.0	17
120	The diflunisal trial: update on study drug tolerance and disease progression. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 196-197.	3.0	20
121	The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 80-82.	3.0	59
122	Treatment of IgM-Associated AL Amyloidosis With the Combination of Rituximab, Bortezomib, and Dexamethasone. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 143-145.	0.4	36
123	Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations. Clinica Chimica Acta, 2011, 412, 1262-1265.	1.1	17
124	The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: A possible impact on the natural history of the disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 87-93.	3.8	22
125	Effects of the Known Pathogenic Mutations on the Aggregation Pathway of the Amyloidogenic Peptide of Apolipoprotein A-I. Journal of Molecular Biology, 2011, 407, 465-476.	4.2	48
126	Variable presentations of TTRâ€related familial amyloid polyneuropathy in seventeen patients. Journal of the Peripheral Nervous System, 2011, 16, 119-129.	3.1	68

#	Article	IF	Citations
127	Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 61-63.	3.0	5
128	Validation of a Diagnostic Score for the Diagnosis of Autoinflammatory Diseases in Adults. International Journal of Immunopathology and Pharmacology, 2011, 24, 695-702.	2.1	50
129	Candidate Genes in Patients with Autoinflammatory Syndrome Resembling Tumor Necrosis Factor Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene. Journal of Rheumatology, 2011, 38, 1378-1384.	2.0	17
130	Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 216-221.	3.0	26
131	Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 92-93.	3.0	21
132	Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Annals of the Rheumatic Diseases, 2011, 70, 1511-1512.	0.9	86
133	Treatment of AL Amyloidosis with Bortezomib Combined with Alkylating Agents: Results From a Prospective Series of Unselected Patients,. Blood, 2011, 118, 3977-3977.	1.4	5
134	The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood, 2010, 116, 3426-3430.	1.4	184
135	Salvage Therapy with Lenalidomide and Dexamethasone (LDex) In Patients with Advanced AL Amyloidosis Refractory to Both Melphalan and Bortezomib. Blood, 2010, 116, 3062-3062.	1.4	0
136	Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine. Clinical Chemistry, 2009, 55, 499-504.	3.2	225
137	Clinical, radiological, and biochemical features of a bilateral buttock amyloidoma emerging after 27 years of hemodialysis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 115-121.	3.0	5
138	Proteomics in protein misfolding diseases. Clinical Chemistry and Laboratory Medicine, 2009, 47, 627-35.	2.3	8
139	Systemic Cardiac Amyloidoses. Circulation, 2009, 120, 1203-1212.	1.6	622
140	Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. Arthritis and Rheumatism, 2009, 61, 1435-1440.	6.7	100
141	Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Annals of Hematology, 2009, 88, 347-350.	1.8	67
142	AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity. Clinical Lymphoma and Myeloma, 2009, 9, 80-83.	1.4	45
143	A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis and Rheumatism, 2008, 58, 1823-1832.	6.7	165
144	Persistent efficacy of anakinra in patients with tumor necrosis factor receptorâ€“associated periodic syndrome. Arthritis and Rheumatism, 2008, 58, 1516-1520.	6.7	297

#	Article	IF	Citations
145	Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.. Blood, 2008, 112, 1689-1689.	1.4	7
146	Late-Onset Familial Mediterranean Fever: An Atypical Presentation of Dermatologic Interest. Archives of Dermatology, 2007, 143, 1073.	1.4	8
147	Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood, 2007, 110, 787-788.	1.4	182
148	Eprodisate for the Treatment of Renal Disease in AA Amyloidosis. New England Journal of Medicine, 2007, 356, 2349-2360.	27.0	240
149	The workings of the amyloid diseases. Annals of Medicine, 2007, 39, 200-207.	3.8	62
150	Infertility and Hypergonadotropic Hypogonadism as First Evidence of Hereditary Apolipoprotein A-I Amyloidosis. Journal of Urology, 2007, 178, 344-348.	0.4	24
151	Report from the Diagnostic Interactive Session. , 2007, , 377-382.		5
152	Prognostic Relevance of Serum N-Terminal Pronatriuretic Peptide Type B and Plasma Bnp in Patients with Al Amyloidosis in Dialysis. , 2007, , 273-274.		0
153	Early Harvest Followed by Melphalan-Dexamethasone and second-Line Autologous Stem Cell Transplantation in Al. , 2007, , 390-392.		0
154	Prolonged Follow-up Study of Al Patients Ineligible for Stem Cell Transplantation Treated with Oral Melphalan and Dexamethasone. , 2007, , 282-282.		0
155	Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2006, 13, 191-205.	3.0	124
156	Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood, 2006, 107, 3854-3858.	1.4	266
157	Neutrophils from patients withTNFRSF1A mutations display resistance to tumor necrosis factorâ€“induced apoptosis: Pathogenetic and clinical implications. Arthritis and Rheumatism, 2006, 54, 998-1008.	6.7	138
158	Early Harvest Followed by Melphalan-Dexamethasone and Second-Line Autologous Stem Cell Transplantation in AL Amyloidosis.. Blood, 2006, 108, 5449-5449.	1.4	0
159	The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood, 2005, 105, 2949-2951.	1.4	207
160	Clinical aspects of systemic amyloid diseases. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1753, 11-22.	2.3	215
161	MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever. European Journal of Human Genetics, 2005, 13, 314-320.	2.8	71
162	A novelAÎ²PP mutation exclusively associated with cerebral amyloid angiopathy. Annals of Neurology, 2005, 58, 639-644.	5.3	81

#	Article	IF	Citations
163	Renal Apolipoprotein A-I Amyloidosis: A Rare and Usually Ignored Cause of Hereditary Tubulointerstitial Nephritis. Journal of the American Society of Nephrology: JASN, 2005, 16, 3680-3686.	6.1	83
164	First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis and Rheumatism, 2004, 50, 2966-2969.	6.7	79
165	Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology, 2004, 126, 1416-1422.	1.3	70
166	Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood, 2004, 103, 2936-2938.	1.4	375
167	Thalidomide plus Intermediate-Dose Dexamethasone in Refractory/Relapsed Al Patients. , 2004, , 115-117.		0
168	Serum N-Terminal Proâ€“Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis. Circulation, 2003, 107, 2440-2445.	1.6	456
169	Conformational Switching and Fibrillogenesis in the Amyloidogenic Fragment of Apolipoprotein A-I. Journal of Biological Chemistry, 2003, 278, 2444-2451.	3.4	86
170	Atypical familial motor neuropathy in patients with mutant TTR Ile68Leu. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 185-189.	3.0	13
171	P3491 Circulating N terminal pro-brain natriuretic peptide as a marker of cardiac dysfunction in AL amyloidosis. European Heart Journal, 2003, 24, 678.	2.2	0
172	Hereditary Amyloidosis. New England Journal of Medicine, 2002, 347, 1206-1207.	27.0	19
173	Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 108-114.	3.0	141
174	Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. Protein Science, 2001, 10, 187-199.	7.6	44
175	Therapeutic advances demand accurate typing of amyloid deposits. American Journal of Medicine, 2001, 111, 243-244.	1.5	46
176	A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. British Journal of Haematology, 2001, 113, 1044-1046.	2.5	67
177	Mutation and transcription analysis of transthyretin gene in Italian families with hereditary amyloidosis: a putative novel â€˜hot spotâ€™ in codon 47. Clinical Genetics, 2001, 57, 284-290.	2.0	11
178	Protein Aggregation. Clinical Chemistry and Laboratory Medicine, 2001, 39, 1065-75.	2.3	29
179	Treatment of AL Amyloidosis with 4â€²-Iodo-4â€²-Deoxydoxorubicin: An Update. Blood, 1999, 93, 1112-1113.	1.4	41
180	Expression, regulation and localisation of dystrophin isoforms in human foetal skeletal and cardiac muscle. Neuromuscular Disorders, 1999, 9, 541-551.	0.6	23

#	Article	IF	Citations
181	The New Apolipoprotein A-I Variant Leu174 â†' Ser Causes Hereditary Cardiac Amyloidosis, and the Amyloid Fibrils Are Constituted by the 93-Residue N-Terminal Polypeptide. American Journal of Pathology, 1999, 155, 695-702.	3.8	108
182	Evidence That Amyloidogenic Light Chains Undergo Antigen-Driven Selection. Blood, 1998, 91, 2948-2954.	1.4	56